Protocol of a randomized, double-blind, placebo-controlled study of the effect of probiotics on the gut microbiome of patients with gastro-oesophageal reflux disease treated with rabeprazole

Liu, Wenjun; Xie, Yong; Li, Yingmeng; Zheng, Longjin; Xiao, Qiuping; Zhou, Xu; Li, Qiong; Yang, Ni; Zuo, Kexuan; Xu, Tielong; Lü, Nonghua; Zhang, Heping

doi:10.1186/s12876-022-02320-y

Cited by 8 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among these, Prevotella melaninogenica, Prevotella pallens, Solobacterium moorei, and Leptotrichia were consistently found at lower levels in the GERD group 21 . Lactobacillus casei Zhang, Bi dobacterium lactis V9, and Lactobacillus plantarum P9 which can effectively regulate the patient's gut microbial dysbiosis have demonstrated the improvement in GRED symptoms in patients with a history of long-term PPI usage 22 . This aligns with the outcomes in the study.…”

Section: Discussionmentioning

confidence: 99%

Roles of gut microbiome in gastroesophageal reflux disease: A Mendelian randomization study

Zhang,

Wang,

et al. 2024

Preprint

View full text Add to dashboard Cite

Increasing evidence has indicated that the gut microbiota is altered in patients diagnosed with gastroesophageal reflux disease (GERD), the exact causal connection between them remains unknown. In this research, we conducted a two-sample Mendelian randomization (MR) analysis using genome-wide association study (GWAS) summary data. The primary analysis employed the inverse-variance weighted (IVW) method. To assess the robustness of our findings, we also conducted additional analyses using the MR-Egger, weighted median, simple mode, and weighted mode methods. Heterogeneity and pleiotropy were examined through the Cochran's Q test, MR-Egger intercept test, and leave-one-out analysis. The present study evaluated the potential causality of gut microbiota in the risk of GERD and found that 10 bacterial taxa, namely class Bifidobacteriaceae, family Christensenellaceae, family ClostridialesvadinBB60group, genus Anaerostipes, genus ChristensenellaceaeR, genus Coprococcus2, genus LachnospiraceaeUCG004, genus Prevotella9, genus Bifidobacteriales, phylum Actinobacteria, may be suggestively causally associated with the risk of GERD.

show abstract

Section: Discussionmentioning

confidence: 99%

Roles of gut microbiome in gastroesophageal reflux disease: A Mendelian randomization study

Zhang,

Wang,

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Finally, some diseases may be caused not by the presence of bacteria per se but by the metabolites produced by bacteria that may be present at higher concentrations following PPI use, and future studies should, to a larger extent, correlate microbiota to the metabolome. Two ongoing studies will provide more evidence about the PPI-induced alteration in microbiota and the association with clinically relevant endpoints in patients with cirrhosis [ 63 ] and in GERD patients [ 64 ].…”

Section: Discussionmentioning

confidence: 99%

Changes in the Gastrointestinal Microbiota Induced by Proton Pump Inhibitors—A Review of Findings from Experimental Trials

Fossmark,

Olaisen

2024

Microorganisms

View full text Add to dashboard Cite

The use of proton pump inhibitors (PPIs) has increased considerably in many Western countries, and there is concern that numerous conditions and diseases associated with PPI use may be adverse events. The main function of gastric acid is to defend the organism against orally ingested microorganisms, and there is also concern that alterations not only in the gastric microbiome but also the downstream intestinal microbiome may increase the risk of disease or alter the course of preexisting disease. The current study is a systematic review of the available evidence from experimental trials investigating the effects of PPIs on the gastrointestinal microbiota by next-generation sequencing. Thirteen studies were identified. The effects of PPIs were seen on alterations in diversity and richness in some of the studies, while a larger proportion of the studies detected alterations at various taxonomic levels. The general finding was that PPI use caused an increase in bacteria normally found in the oral microbiota in both the upper and lower GI tract. The most consistent taxonomic alterations seemed to be increases in oral flora along the axis Streptococcaceae and Streptococcus at genus level and various Streptococcus spp., as well as Veillonellaceae, Veillonella and Haemophilus.

show abstract

“…In children, once daily co-administration of probiotics substantially reduced dysbiosis occurrence in response to 12-week, once daily esomeprazole vs. esomeprazole treatment alone from 56.2% to 6.2%, respectively (92). Other studies report mixed findings regarding the beneficial effects of supplementation with Streptococcus, Lactobacillus and/or Bifidobacterium on body weight, BMI, waist circumference, and fat mass (97). A clinical trial analyzing the effects of probiotics to reduce dysbiosis and GI discomfort in adult GERD patients using PPIs long-term is currently underway (98).…”

Section: Discussionmentioning

confidence: 99%

“…Other studies report mixed findings regarding the beneficial effects of supplementation with Streptococcus , Lactobacillus and/or Bifidobacterium on body weight, BMI, waist circumference, and fat mass ( 97 ). A clinical trial analyzing the effects of probiotics to reduce dysbiosis and GI discomfort in adult GERD patients using PPIs long-term is currently underway ( 98 ). The benefits of probiotic use outweigh any potential risks.…”

Section: Discussionmentioning

confidence: 99%

Evidence for proton-pump inhibitor (PPI)-associated dysbiosis in metabolically unhealthy obesity

et al. 2023

View full text Add to dashboard Cite

Obesity adversely impacts millions of American adults by predisposing them to significant health risks and further complications. Obesity is differentiated into two groups: metabolically healthy and metabolically unhealthy. In contrast to metabolically healthy counterparts, obese individuals who are metabolically unhealthy display hallmark symptoms of metabolic syndrome (e.g., hypertension, dyslipidemia, hyperglycemia, abdominal obesity). Gastroesophageal reflux disease (GERD) commonly occurs in all obese populations, as do poor dietary habits. Proton-pump inhibitors (PPIs), due to their wide availability, are most often used to treat GERD-related heartburn and other symptoms. Here, we review the evidence on how poor diet as well as short- and long-term use of PPIs adversely affect the gastrointestinal microbiota to cause dysbiosis. Key components of dysbiosis-induced metabolically unhealthy obesity (MUO) associated with PPI use include “leaky gut,” systemic low-grade inflammation, and reduced amounts of short-chain fatty acids (SCFAs) such as butyrate that promote metabolic health. The benefit of using probiotics to mitigate PPI-induced dysbiosis and MUO is also discussed.

show abstract

Protocol of a randomized, double-blind, placebo-controlled study of the effect of probiotics on the gut microbiome of patients with gastro-oesophageal reflux disease treated with rabeprazole

Cited by 8 publications

References 26 publications

Roles of gut microbiome in gastroesophageal reflux disease: A Mendelian randomization study

Roles of gut microbiome in gastroesophageal reflux disease: A Mendelian randomization study

Changes in the Gastrointestinal Microbiota Induced by Proton Pump Inhibitors—A Review of Findings from Experimental Trials

Evidence for proton-pump inhibitor (PPI)-associated dysbiosis in metabolically unhealthy obesity

Contact Info

Product

Resources

About